Children and adults with malignant diseases have a high risk of prevalence of the tumor in the central nervous system (CNS). As prophylaxis treatment methotrexate is often given. In order to monitor methotrexate exposure in the CNS, cerebrospinal fluid (CSF) concentrations are often measured. However, the question is in how far we can rely on CSF concentrations of methotrexate as appropriate surrogate for brain target site concentrations, especially under disease conditions.
INTRODUCTION
Methotrexate was introduced into the treatment of malignant diseases more than 50 years ago (Hertz et al., 1956) . Today, many treatment protocols for malignant diseases, like acute lymphoblastic leukemia, have established the combination of high-dose methotrexate (to decrease the fraction of plasma protein binding), combined with leucovorin rescue (Djerassi et al., 1967; Moe and Holen, 2000) . Before the use of central nervous system (CNS) prophylaxis, the CNS was the most frequently reported site of initial recurrence in children with acute lymphoblastic leukemia, accounting for up to 75% of cases (Bleyer and Poplack, 1985; Evans et al., 1970) . However, in the treatment of acute lymphoblastic leukemia, prophylactic CNS therapy effectively reduced the rate of CNS relapses (Balis and Poplack, 1989; Blaney and Poplack, 1996, Clarke et al., 2003; Smith et al., 1996) . Still, CNS recurrence remains a major limitation to achieving complete cure, accounting for 30-40% of recurrences in some pediatric clinical trials (Hutchinson et al., 2003; Lange et al., 2002) .
The use of cranial irradiation for CNS prophylaxis is effective but associated with severe late effects (Clarke et al., 2003; Ochs and Mulhern, 1994) . Today, the combination of high-dose methotrexate and intrathecal methotrexate, employed to reduce such treatment-related late effects, has successfully replaced cranial irradiation as CNS prophylaxis in most patients (about 80 to 90%) of acute lymphoblastic leukemia (Cáp et al., 1998; Pui et al., 2009 ). However, the intrathecal methotrexate procedure is susceptible to complications and stressful for the patient, especially for children (Keidan et al., 2005) . Therefore, it has been suggested that the use of high-dose intravenous methotrexate alone could be sufficient for CNS prophylaxis (Niemann et al., 2010) .
On the basis of in vitro testing, a methotrexate concentration of 0.45 µg/ml at the target site is commonly acknowledged as effective in killing tumor cells (Hryniuk and Bertino, 1969) . With the CNS being the target site for CNS prophylaxis, it is the aim to have the appropriate methotrexate concentration in the brain extracellular fluid (brain ECF ). However, as blood-brain barrier (BBB) transport is highly restricted for methotrexate, plasma concentrations need to be far higher than the 0.45 µg/ml to be able to reach appropriate concentrations in the CNS. As a result, the exposure of the rest of the body to cytotoxic concentrations is quite substantial (Chabner and Young, 1973; Ferreri et al., 2004) .
The information on the relationship between plasma and CNS methotrexate concentrations appears to be inconsistent, with linear relationships reported by Borsi and Moe (1987) , Jönsson et al. (2007) , Millot et al. (1994) , whereas Milano et al. (1990) , Thyss et al. (1987) and Vassal et al. (1990) reported nonlinear relationships. Therefore, CNS concentrations are often monitored for appropriate dose selection (Niemann et al., 2010) . To that end, CSF concentrations are used, since brain ECF concentrations are not readily measurable in humans. CSF concentrations are considered to be the best available surrogate (Fridén et al., 2009; Kalvass and Maurer, 2002; Liu et al., 2006; Liu et al., 2009; Maurer et al., 2005) , with the assumption that CSF concentrations readily equilibrate with brain ECF concentrations due to the lack of a physical barrier between these sites (Lee et al., 2001 ). However, due to qualitative and quantitative differences between processes that govern the pharmacokinetics (PK) of drugs in the brain ECF versus CSF, a generally applicable relationship between the PK at these two sites does not exist and needs evaluation (Chapter 1; De Lange and Danhof, 2002; Lin, 2008; Shen et al., 2004) .
We have previously shown that even for acetaminophen, investigated as model compound for passive transport into, within and out of the brain, differences exist between CSF and brain ECF kinetics (Chapter 3). Furthermore, we have also shown that for quinidine, a model compound for P-gp mediated transport, differences exist between CSF and brain ECF kinetics, which are very much dependent on P-gp functionality (Chapter 4). With methotrexate being a substrate for a wide variety of transporters that are all located at the BBB and BCSFB (including the reduced folate carrier 1 (RFC1) (Hinken et al., 2011) , breast cancer resistance protein (BCRP) (Breedveld et al., 2007) , multidrug resistance-associated proteins (MRP) 2, 3 and 4 (Vlaming et al., 2011) , organic anion transporter (OAT) 1 and 3 (Takeda et al., 2002) , and organic aniontransporting polypeptides (OATP) A (Badagnani et al., 2006) and OATP B (van de Steeg et al., 2009) ), this could have major implications for the predictability of brain ECF methotrexate concentrations on the basis of CSF concentrations. Consequently, to be able to know whether methotrexate brain ECF concentrations can be adequately predicted by CSF concentrations, one should first understand the mechanisms that determine the relationship between CSF concentrations and brain ECF concentrations.
In this study we have used the parallel intracerebral microdialysis probes approach (striatum, lateral ventricle, and cisterna magna (Chapter 3)) in conjunction with parallel blood sampling, for continuous measurement and direct comparison of changes in concentrations in plasma, brain ECF and CSF kinetics of methotrexate. To investigate the specific contribution of the various transporters, probenecid is co-administered as inhibitor of MRPs (Bakos et al., 2000) , OATs (Sugiyama et al., 2001) and OATPs (Kis et al., 2013) . Advanced mathematical modeling is applied to extrapolate the data to other conditions, and other species, including human.
MATERIALS AND METHODS

Chemicals and solutions
Methotrexate solution for injection (Emthexate PF) and isoflurane were obtained from Pharmachemie B.V. (Haarlem, the Netherlands). Methotrexate (powder), aminopterin and ammonium formate were from Sigma-Aldrich (Zwijndrecht, the Netherlands). Probenecid, 5% glucose and saline were obtained from the Leiden University Medical Centre pharmacy (Leiden, the Netherlands). Acetonitrile (HPLC-S grade), methanol (ULC-grade) and formic acid (ULC grade) were from Biosolve (Valkenswaard, the Netherlands). Ammonium hydroxide (25%), magnesium chloride, sodium acetate, sodium chloride, calcium chloride and perchloric acid, were obtained from Baker (Deventer, the Netherlands). Potassium chloride was from Merck (Darmstadt, Germany). All other chemicals were of analytical grade. Microdialysis perfusion fluid was prepared as previously described (Chapter 3), containing 140.3 mM sodium, 2.7 mM potassium, 1.2 mM calcium, 1.0 mM magnesium and 147.7 mM chloride.
Animals
The study protocol was approved by the Animal Ethics Committee of Leiden University (UDEC nr. 10094). All animal procedures were performed in accordance with Dutch laws on animal experimentation. A total of 40 male Wistar WU rats (225-275 g, Charles River, Maastricht, the Netherlands) were randomly divided into two groups; the first group (n = 8) was used for the determination of the in vivo microdialysis probe recovery; the second group (n = 32) was used for brain disposition experiments. This second group was further divided into four subgroups, designated for 40 or 80 mg/kg methotrexate without or with co-administration of probenecid (denoted as 40 -, 40 + , 80 -and 80 + , respectively).
After arrival, all animals were housed in groups for 5-7 days (Animal Facilities, Gorlaeus Laboratories, Leiden, the Netherlands), under standard environmental conditions (ambient temperature 21°C; humidity 60%; 12/12 h light/dark cycle, background noise, daily handling), with ad libitum access to food (Laboratory chow, Hope Farms, Woerden, the Netherlands) and acidified water. Between surgery and experiments, the animals were kept individually in Makrolon type three cages for 7 days to recover from the surgical procedures.
Surgery
All surgical procedures were performed as described in Chapter 3. In short, cannulas were implanted in the left femoral artery and vein for blood sampling and drug administration, respectively. Both cannulas were subcutaneously led to the back of the head and fixated in the neck with a rubber ring. Subsequently, the animals were chronically instrumented with two CMA/12 microdialysis guides (CMA/Microdialysis AB, Stockholm, Sweden) in different combinations of striatum (ST), for sampling in brain ECF , and lateral ventricle (LV) and/or cisterna magna (CM) for sampling in CSF (ST+LV, ST+CM or LV+CM). For ST, the position of the microdialysis guide is: 1.0 mm anterior, 3.0 mm lateral, 3.4 mm ventral, relative to bregma. For LV, the position of the microdialysis guide is: 0.9 mm posterior, 1.6 mm lateral, 2.9 mm ventral, relative to the bregma. For CM, the position of the microdialysis guide is: 1.93 mm posterior, 3.15 mm lateral, 8.1 mm ventral, at an angle of 25° from the dorsoventral axis (towards anterior) and 18° lateral from the anteroposterior axis relative to lambda. The microdialysis guides were secured to the skull with 3 anchor screws and dental cement.
After the surgery the animals received 0.03 ml Temgesic ® intramuscularly (Schering-Plough, Amstelveen, the Netherlands) and 0.3 ml Ampicillan® (Alfasan B.V., Woerden, the Netherlands) subcutaneously. One day prior to the experiment, the microdialysis dummies were replaced by the microdialysis probes (CMA/12 Elite, Polyarylethersulfone membrane, molecular weight cutoff 20 kDa, CMA/Microdialysis AB, Stockholm, Sweden, with a semipermeable membrane length of 4 mm for ST, and 1 mm for LV and CM).
Experimental set-up
All experiments were performed as described in Chapter 4, with some modifications. In short, the in vivo microdialysis probe recovery of methotrexate was determined on the basis of reverse dialysis (Ståhle et al., 1991) . The microdialysis probes in striatum, lateral ventricle and cisterna magna were perfused with different concentrations of methotrexate (50, 200 and 1000 ng/ml) in perfusion fluid. To evaluate the potential effect of co-administration of probenecid on the in vivo recovery of methotrexate, several animals received an intravenous infusion of 150 mg/kg probenecid in 5% NaHCO 3 in saline (150 µl/min/kg for a period of 10 minutes) with an automated pump (Pump 22 Multiple Syringe Pump, Harvard Apparatus, Holliston, USA) 30 minutes prior to the start of the reverse dialysis experiment. Control animals received an intravenous infusion of vehicle (150 µl/min/kg, for a period of 10 minutes).
The in vivo recovery is defined as the ratio of the concentration difference between the dialysate (C dial ) and perfusion fluid (C in ) over the concentration in the perfusion fluid (equation 1) (Scheller and Kolb, 1991) .
For the brain disposition experiments, the rats first received an intravenous infusion of 150 mg/kg probenecid in 5% NaHCO 3 in saline or vehicle (150 µl/min/kg, for a period of 10 minutes) 30 minutes prior to the administration of 40 or 80 mg/kg methotrexate in saline (200 µl/min/kg for a period of 10 minutes). The start and duration of the infusion was corrected for internal volume of the tubing so that infusion started at t=0 min. 10 min interval samples were collected between t=−1 h and t=5 h. After weighing the microdialysis vials they were stored at −80°C before analysis.
For the determination of methotrexate plasma concentrations, blood samples of 100 μl were taken, in parallel to the microdialysate samples, from the arterial cannula at t=−5 (blank), 2, 7, 9, 10, 12, 17, 30, 90, 180 , and 300 min. All blood samples were temporarily stored in heparin (10 IU) coated Eppendorf cups before being centrifuged for 15 min at 5000 rpm. The plasma was then pipetted into clean Eppendorf cups and stored at −20°C before analysis.
At the end of the experiments the animals were sacrificed with an overdose of Nembutal (Ceva Sante Animale, Libourne, France).
Plasma protein binding
For the determination of plasma protein binding of methotrexate, plasma samples of different time points were pooled (combining t = 2 and 7; t = 9 and 10; t = 12 and 17; t = 30 and 90; t = 180 and 300) to span the entire concentration range. Plasma protein binding was determined with Centrifree® ultrafiltration devices (Millipore BV, Etten-Leur, the Netherlands). All procedures were performed according to the user's manual. The ultrafiltrate was diluted 10 times with saline before the analysis.
Concentration analysis
Methotrexate concentrations in plasma, plasma ultrafiltrate and microdialysate were quantified using an on-line solid phase extraction (SPE) with liquid chromatography-tandem mass spectrometry (LC/MS/MS) system, based on previous work by Rule et al. (2001) and Guo et al. (2007) .
To 20 µl of plasma and plasma ultrafiltrate, 20 µl internal standard (10 µg/ml aminopterin) was added. After mixing with 40 µl of 6% perchloric acid and centrifugation for 10 minutes at 10000 g, 60 µl of the supernatant was thoroughly mixed with 40 µl of 1 M sodium acetate. 20 µl was then injected on the SPE column.
To 15 µl of the microdialysate samples, 15 µl of the internal standard (250 ng/ml aminopterin) was added. After mixing, 10 µl was injected on the SPE column.
HySphere™ SPE cartridges and a cartridge holder from Spark (Emmen, the Netherlands) were used in combination with the divert/inject valve of the mass spectrometer to prevent salt entering the mass spectrometer. After flushing under acidic conditions, the SPE was switched onto the LC system and methotrexate and its internal standard were eluted from the SPE to the LC column. For plasma precipitates, C-8 HD SE cartridges were used, while for microdialysate samples C-18 cartridges were used. After injection of the sample on the SPE column, salts from either precipitated plasma or microdialysate samples were flushed to waste before analysis on the HPLC column. A quaternary gradient HPLC pump (P580) from Dionex (Breda, the Netherlands) was used for the on-line SPE method, while a Surveyor pump (Thermo Scientific, Breda, the Netherlands) served as delivery unit for the HPLC column.
The VisionHT® C-18B column (Grace Alltech, Breda, the Netherlands) was thermostatted at 37°C. The mobile phase consisted of 21% methanol and 79% lab water, derived from a PURELAB Ultra system (Veolia Water Solutions, Ede, the Netherlands), containing 0.2% formic acid and 1 mM ammonium formate. After isocratic elution of the peaks of methotrexate and internal standard, the column was flushed with 90% methanol and 10% lab water containing 0.2% formic acid and 1mM ammonium formate 7-9.5 minutes after injection.
Sample analysis was performed on a Finnigan TSQ Quantum Ultra Mass Spectrometer System (Thermo Scientific, Breda, the Netherlands). Electrospray ionization was used in the positive mode at 3500V. Methotrexate was quantified using selected reaction monitoring (SRM) with the transition 455-308 (m/z). The internal standard, aminopterin, had a SRM transition of 441-294 (m/z). The collision energy used was 18 V, scan width was set at 0.7 m/z and both Q1 and Q3 were set to 0.70 full width at half maximum (FWHM). The scan time was 0.11 seconds. Argon served as the collision gas.
Pharmacokinetic data analysis
All plasma concentrations were converted to unbound plasma concentrations, by correction for plasma protein binding. All microdialysate concentrations from striatum, lateral ventricle and cisterna magna were converted into brain ECF concentrations (C ECF ) or CSF concentrations (C CSF ) by division of the dialysate concentrations by the average in vivo recovery as determined for each microdialysis probe location (equation 2).
Areas under the curve from t=0 to t=300 min (AUC 0-300 ) were calculated by the trapezoidal rule and tested for differences by single factor ANOVA. The population PK models were developed and fitted to the data by means of nonlinear mixed-effects modeling using the NONMEM software package (version 6.2, Icon Development Solutions, Ellicott City, Maryland, USA) and analyzed using the statistical software package S-Plus® for Windows (version 6.2 Professional, Insightful Corp., Seattle, USA).
The pharmacokinetic model for methotrexate plasma and brain concentrations was based on the systems-based PK (SBPK) approach we have previously applied to investigate the exchange between brain ECF and CSF of acetaminophen (Chapter 3) and quinidine (Chapter 4). For this approach, the volumes of the different brain compartments were fixed to their physiological volumes. The rat brain intracellular space and brain ECF volume were assumed to be 1.44 ml (Thorne et al., 2004) and 290 µl (Cserr et al., 1981) , respectively. With a total CSF volume of 300 µl in the rat (Bass and Lundborg, 1973) , the volumes of the lateral ventricles, third and fourth ventricles, cisterna magna and subarachnoid space were assumed to be 50 µl (Condon et al., 1986; Kohn et al., 1991) , 50 µl (Levinger, 1971) , 17 µl (Adam and Greenberg, 1978; Robertson, 1949) and 180 µl (Bass and Lundborg, 1973; Levinger, 1971) , respectively. The intra-brain distribution was restricted by the physiological flow paths of brain ECF , in which brain ECF flows towards the CSF compartments at a rate of 0.2 μl/min (Abbott, 2004; Cserr et al., 1981) , and CSF flows from lateral ventricle, through the third and fourth ventricle, to the cisterna magna and subsequently to the subarachnoid space (cranial and spinal) and back into blood at a rate of 2.2 μl/min (Cserr, 1965) .
Structural model selections for both the blood and brain PK model were based on the likelihood ratio test (p < 0.01), diagnostic plots (observed concentrations vs. individual and population predicted concentrations, weighted residuals vs. predicted time and concentrations), parameter correlations and precision in parameter estimates. The inter-animal variability in pharmacokinetic parameters was assumed to be log normally distributed. The residual error, which accounts for unexplained variability (e.g. measurement and experimental error and model-misspecification), was best described with a proportional error model.
The validity of the pharmacokinetic models was investigated by means of a visual predictive check. (Cox et al., 1999; Duffull and Aarons, 2000; Yano et al., 2001) Using the final PK parameter estimates, 1000 curves were simulated. Subsequently, the median and the 5 th and 95 th percentile of the predicted concentrations were calculated, which represent the 90% prediction interval. These were then compared with the observations. In order to test the ruggedness of the model and estimate the precision of the parameters n=100 non-parametric (case resampling) bootstraps were performed. To create the bootstrapped datasets, specific rat data (plasma and microdialysate concentrations) were removed randomly from the datasets and replaced with randomly selected rat data from the complete original dataset. Each of these permutations of the original dataset was fitted with the final model determined based on the original dataset. This results in a series of model fits, each with its own set of parameters. These results were displayed graphically and the descriptive statistics of the parameters were compared to parameter estimates of the final model. Only bootstrap runs that successfully minimized were used in this analysis.
Systems-based scaling
The SBPK model was first used to predict the methotrexate plasma and brain ECF concentration-time profiles of brain tumor-bearing rats (De Lange et al., 1995) , to investigate the impact of disease-status on the kinetics of methotrexate. Next, the parameters of the rat SBPK were extrapolated to healthy dogs (Neuwelt et al., 1985) , to investigate the validity of using this approach for interspecies scaling. To do so, the elimination clearance was first divided into renal clearance and hepatic clearance, with renal clearance assumed to be identical to the glomerular filtration rate (Brcakova et al., 2009 ) and the remaining clearance assigned to hepatic clearance. The hepatic clearance was then scaled to the number of hepatocytes in rat or dog liver. Next, the transfer clearances between plasma and the different peripheral and brain compartments were scaled based on
In which A PER and A BR are scaling coefficients for periphery and brain, respectively, and both are estimated on the basis of the rat data (HosseiniYeganeh and McLachlan, 2002) . V PER represents the physiological volume of the (lumped) peripheral tissues for rapid (including muscle, kidney, intestine and liver) and slow equilibration (including adipose, skin, heart, bone and remaining tissue). V BR represents the physiological volume of the different brain compartments. The scaling factor of 0.67 is based on the permeability surface area of the different brain compartments, which is related to the tissue weight (Kawai et al., 1994) . The physiological parameters of the rat SBPK model were changed accordingly. Finally, the parameters of the rat SBPK were extrapolated to the human setting, which included adults and children with different disease-states, using the same approach as applied for extrapolation to dogs.
RESULTS
All results are presented as average values ± standard error of the mean, unless stated otherwise.
Methotrexate pharmacokinetics
The average unbound plasma (plasma u ), brain ECF , lateral ventricle (CSF LV ) and cisterna magna (CSF CM ) methotrexate concentrations following the 40 and 80 mg/kg dose with or without co-administration of probenecid are shown in figure 1. Plasma protein binding of methotrexate was linear at an extent of 55.2 ± 7.7%. It was not affected by co-administration of probenecid. The coadministration of probenecid slightly altered the distribution phase for both the 40 and 80 mg/kg dose of methotrexate. Data obtained by microdialysis from the brain ECF , CSF LV and CSF CM were corrected for in vivo recovery. The average in vivo recoveries for the methotrexate concentrations in striatum, lateral ventricle and cisterna magna probes were influenced by co-administration of probenecid and were determined to be 22.1 ± 2.0%, 28.1 ± 2.9% and 35.9 ± 2.5%, for the control group and 7.1 ± 0.9%, 16.9 ± 1.7% and 21.6 ± 5.6% for the probenecid group, respectively.
It can be seen that a higher dose of methotrexate leads to higher methotrexate concentrations in all brain compartments, but not to the same extent. Probenecid increased methotrexate concentrations significantly (p < 0.01) in all brain compartments. The effect of probenecid was dependent on the methotrexate dose; at the higher dose of methotrexate, the increase in methotrexate concentrations was more profound for brain ECF and CSF LV , as can be seen by the average unbound brain (brain u )-to-plasma u AUC 0-300 ratios (table  1) . However, the dose-dependency was not significant. The relationship between brain ECF -to-CSF concentration ratios was not significantly affected by probenecid co-administration, and was on average 7.7 ± 3.7 (table 2). Brain ECF -to-CSF LV 9.6 ± 5.0 6.0 ± 2.9 11.6 ± 7.0 5.2 ± 2.4
E.M.) unbound methotrexate concentration-time profiles following intravenous administration of methotrexate, with (+) or without (-) co-administration of probenecid (150 mg/kg). (A) 40 mg/kg methotrexate dose: for plasma (n = 7 (-) and 6 (+)), brain ECF (n = 5 (-) and 4 (+)), CSF LV (n = 4 (-) and 3 (+)) and CSF CM (n = 3 (-) and 4 (+). (B) 80 mg/kg methotrexate dose. Plasma (n = 7 (-) and 7 (+)), brain ECF (n = 4 (-) and 5 (+)), CSF LV (n = 5 (-) and 4 (+)) and CSF CM (n = 6 (-) and 3 (+))
Brain ECF -to-CSF CM 11.5 ± 5.5 8.3 ± 1.6 6.0 ± 2.3 12.7 ± 3.0
Brain ECF -to-CSF average 10.2 ± 4.8 6.8 ± 2.1 7.6 ± 3.3 7.2 ± 2.7
Systems-based modeling approach
As it was our goal to investigate the relationship between brain ECF and CSF pharmacokinetics, we have applied a SBPK modeling approach like we did previously for analysis of regional brain distribution of acetaminophen (Chapter 3) and quinidine (Chapter 4). To adequately describe CSF physiology, we have used four CSF compartments that represent the CSF LV , the combined third and fourth ventricle (CSF TFV ), the CSF CM and the subarachnoid space (CSF SAS ). Since we have no measurements of the concentrations in the third and fourth ventricle, the transfer clearance between plasma and third and fourth ventricle was assumed to be equal to the transfer clearance between plasma and lateral ventricle.
Distinction between passive and active transport clearances -The active component of the different transfer clearances between plasma and the brain compartments was determined by comparing the parameter estimations for the rats that did to those rats that did not receive the co-administration of probenecid. Even though methotrexate is transported by a wide variety of transporters, the co-administration of the Mrp-, Oat-and Oatp-inhibitor probenecid allowed us to investigate the impact of combined Mrp-, Oat-and Oatp-mediated transport. The active component of the transfer clearances between plasma and the different brain compartments was incorporated into the model as previously described by Syvänen et al. (2006) :
Where the subscript 'p' denotes passive transport and 'a' denotes active transport. For the animals that received a co-administration of probenecid, both CL PL-BR,a and CL BR-PL,a were considered to be 0.
Modeling Mrp-, Oat-and Oatp-mediated transport -Both Mrps, Oats, as well as Oatps have been well described as efflux transporters at the BBB and BCSFB (Graff and Pollack, 2004) . However, the mechanism by which Mrps, Oats and Oatps can exert their effect could be by reducing the transfer clearance from plasma to the brain compartments (i.e. influx hindrance; equation 5) or by increasing the transfer clearance from the brain compartments to plasma (i.e. efflux enhancement; equation 6) or both. The data were best described by the model with Mrp, Oat and Oatp functioning solely by influx hindrance. Interestingly, the observation that in vivo probe recovery of methotrexate was affected by probenecid indicates that methotrexate is transported by Mrps, Oats and Oatps via the efflux enhancement mechanism (Syvänen et al., 2006) . However, estimation of the active components when Mrp, Oat and Oatp were considered to function by efflux enhancement resulted in too large coefficients of variation. Also, the estimation of the active component in the transfer between plasma and cisterna magna resulted in too large coefficients of variation and was therefore assumed to be absent.
Modeling methotrexate concentration-dependent Mrp-, Oat-or Oatpmediated transport -Since Mrp-, Oat-or Oatp-mediated transport is an active (saturable) process we have also tried to identify the maximal transport rate (T m ) and the blood-or brain concentration for half-maximal transport (K m ) as follows:
Where C PL,u is the unbound plasma concentration and C BR is the concentration in one of the brain compartments. The parameter estimations of T m and K m resulted in high values for both T m and K m (results not shown), indicating that the plasma and brain concentrations in this study are not sufficiently high for saturating Mrp-, Oat-or Oatp-mediated transport. The parameter estimations of T m and K m also resulted in too large coefficients of variation. Thus, our data were insufficient to determine the values of these parameters. Therefore, Mrp-, Oat-or Oatp-mediated transport had to be incorporated by means of a single active transport clearance value, rather than by T m and K m .
Final SBPK model -The final SBPK model is shown in figure 2 . The differential equations of this model can be found in the appendix. The final estimation of the PK parameters is summarized in table 3. Interestingly, no active component on the elimination clearance could be identified, whereas this was the case for the compartmental pharmacokinetic analysis of the plasma concentrations only (results not shown). According to Brcakova et al. (2009) , the rate of renal clearance of unbound methotrexate in rats equals the rate of renal creatinine clearance, which is a measure of the glomerular filtration rate (GFR; 1.4 ml/min in the rat (Atherton, 1983) ). Consequently, the remaining methotrexate clearance is hepatically. Based on our results, the rate of hepatic clearance is therefore 7.35 ml/min in the rat. With a total hepatic blood flow of approximately 11.8 ml/min (Davies and Morris, 1993) , this results in a hepatic extraction ratio of 62%, which is comparable to the 53% reported previously by Kates and Tozer (1976) . The visual predictive check of the final model is given in figure 3 . It can be seen that the final model describes the data very well within the 90% prediction interval, and also can cope with the large inter-individual variation in brain concentrations.
Figure 3. The visual predictive check of the final SBPK model. The dots represent the individual data points and the gray area represents the 90% prediction confidence interval. The different boxes represent the plasma u , brain ECF , CSF LV and CSF CM data
Systems-based scaling
The physiological and PK parameters of the rat, dog and human children and adults that were used for the extrapolation are given in table 3. Cserr et al., 1981; 4 Cserr, 1965; 5 Lee and Blaufox, 1985; 6 Davies and Morris, 1993;  7 Bass and Lundborg, 1973; 8 Condon et al, 1986; 9 Kohn et al., 1991; 10 Levinger, 1971; 11 Adam and Greenberg, 1978; 12 Robertson, 1949; 13 Henderson et al., 1965; 14 Von Hendy-Willson and Pressler, 2011; 15 Bering, 1959; 16 Visser et al., 1982; 17 Löfgren et al., 1973; 18 Vladic et al 2009; 19 Skibińska et al., 1990; 20 Hendel and Brodthagen, 1984; 21 Schwartz et al., 1976;  22 Kimelberg, 2004; 23 Yasuda et al., 2002; 24 Linderkamp et al., 1977; 25 ICRP, 2002;  26 Thorne et al., 2004; 27 Dekaban and Sadowsky, 1978; 28 Troncin and Dadure, 2009; 29 Nilsson et al., 1992; 30 Frank and Gray, 1953; 31 Dickey et al., 2000; 32 Pardridge, 2011. 
Extrapolation to other healthy and to diseased rats
We have applied the final SBPK model to investigate the impact of diseasestatus on the PK of methotrexate in plasma u and brain ECF of brain tumor-bearing rats, compared to healthy control rats (De Lange et al., 1995) . By using the same PK parameter values that were estimated based on our data (table 3) , there appears to be a small underestimation of the elimination from plasma as well as a small underestimation of the initial brain ECF concentrations for the control rats (figure 4A) (but both plasma u and brain ECF data are in general still within the range of 5-95% of the model prediction of the data). However, for the group of rats with measurement of plasma and ipsilateral brain ECF concentrations at 11 days post-tumor implantation, the concentration-time profiles in brain ECF in brain tumor were substantially higher than was the case for the healthy situation ( figure 4B ). Presence and size of tumor were determined histologically after the end of the experiment. Simulations indicated that these higher brain ECF concentrations are most likely caused by an increased plasma-to-brain ECF clearance rate in brain tumor conditions (results not shown). 
Extrapolation to healthy dogs
We have also tried to predict the plasma u and CSF kinetics of methotrexate in healthy dogs by systems-based scaling of our rat data. Predictions were then compared to literature data presented by Neuwelt et al. (1985) . Plasma concentrations were first corrected for the level of protein binding, which was assumed to be 40% (Henderson et al., 1965) . The rate of renal clearance was assumed to equal the glomerular filtration rate (80.2 ml/min (Von HendyWillson and Pressler, 2011)). Systems-based scaling of our data initially resulted in a 10-to-100-fold underestimation of dog plasma u and CSF CM concentrations, whereas the CSF CM -to-plasma u concentration ratio was predicted correctly. The underestimation of the plasma u and CSF CM concentrations was primarily caused by an overestimation of the plasma elimination clearance. As the number of hepatocytes per gram liver in dogs is twice as much compared to rats (Bayliss et al., 1999) , the rate of hepatic clearance was scaled to the liver weight and then multiplied by 2. With an assumed liver weight of 720 g in the dog (Davies and Morris, 1993) , the rate of hepatic clearance was estimated to be 1094 ml/min. However, in the rat, methotrexate is eliminated both via the kidneys as well as the liver, whereas in dogs methotrexate is eliminated primarily via the kidneys (Henderson et al., 1965) . This indicates that the estimation of the hepatic clearance rate in dogs was much too high. For healthy dogs, with a hepatic clearance being approximately 10% of the renal clearance (Henderson et al., 1965) , using the physiological and adapted PK parameters presented in table 3, the prediction was much improved and resulted in a slight underestimation of plasma u and CSF CM concentrations ( figure 5 ). Yet the CSF CM -to-plasma u concentration ratio was still predicted correctly. Neuwelt et al. (1985) 
Extrapolation to diseased human adults and children
The only available human brain ECF concentration-time profiles were derived from Blakeley et al. (2009) , from 2 adult patients with supratentorial glioma. Other data included human plasma and CSF LV concentration-time profiles in adults with meningeal leukemia or meningeal carcinomatosis (n = 21, Shapiro et al., 1975) , primary tumor (n = 16, Glantz et al., 1998) , or only plasma concentration-time profiles in adults with small-cell lung carcinoma (n = 9, Creaven et al., 1976) , various neoplastic diseases (n = 8, Bore et al., 1987) or rheumatoid arthritis (n = 56, Herman et al., 1989; Stewart et al., 1990) . Also included were plasma and CSF CM concentration-time profiles from children with medulloblastoma or ependymoblastoma (n = 4, Chatelut et al., 1991) , plasma and CSF SAS concentration-time profiles from children with nonHodgkin's lymphoma (n = 29, Vassal et al., 1990) , or only plasma concentration-time profiles from children with acute lymphoblastic leukemia (n = 49, Aumente et al., 2006) or osteosarcoma (n = 14, Colom et al., 2009) . For constructing the adult and child plasma, CSF LV , CSF CM and CSF SAS dataset, either the individual or average data points from the different references were used, when available. Otherwise, simulations were performed based on the PK parameters presented in the different references.
All plasma concentrations were first corrected for the level of protein binding, which was assumed to be 32% for high dose methotrexate (Skibińska et al., 1990) . Systems-based scaling of our data initially resulted in a 100-fold underestimation of human plasma u , brain ECF and CSF concentrations for both adults and children (results not shown). Again, the underestimation of the plasma u , brain ECF and CSF concentrations was primarily caused by an overestimation of the elimination clearance. For the systems-based scaling of the elimination clearance of methotrexate it was assumed that the rate of human renal clearance equals the glomerular filtration rate (125 ml/min in adults (Davies and Morris, 1993) and approximately 80 ml/min in 9 year-old children (the average age of the available datasets)). As the number of hepatocytes per gram liver is equal between rats and humans (Bayliss et al., 1999) , the rate of hepatic clearance is scaled to the liver weight. With an assumed liver weight of 10 g in the rat (Davies and Morris, 1993) , 780 g in 9 year old children and 1820 g in adults (ICRP, 2002) , the rate of hepatic clearance is estimated to be 593 ml/min and 1380 ml/min in 9 years old children and adults, respectively. However, due to the extensive enterohepatic circulation of methotrexate in humans, the hepatic elimination rate is effectively reduced to the same level as the renal elimination rate (Hendel and Brodthagen, 1984) . So, when taking into account that the hepatic clearance rate of methotrexate in humans is much lower than the extrapolated value, i.e. equal to the renal clearance rate, the predicted human plasma u concentrations are comparable to the observed concentrations (figure 6). However, even though the human plasma u concentrations can be predicted reasonably well with systems-based scaling of our rat data and adaption of the hepatic clearance rate to those reported for human (table 3) , this approach still results in an up to 10-fold underestimation of brain ECF , CSF CM and CSF LV concentrations in both children and adults, respectively. Scaling of the blood-to-brain clearance values on the basis of the total surface area of the BBB (150 cm 2 in rats (Gjedde, 1981; Keep and Jones, 1990a) ; 200,000 cm 2 in human adults (Pardridge, 2002) ) and BCSFB (75 cm 2 in rats (Keep and Jones, 1990b) , 2000-100,000 cm 2 in human adults (Dohrmann, 1970) ), rather than to the tissue weight to the power 0.67, did not improve the predictions (results not shown). Brain ECF and CSF LV concentrations in adults, as shown in figure 6a, were not obtained in parallel, but from different subjects, also having other diseases. However, these are the only data available to make a comparison between these two unbound brain concentrations. Both brain ECF and CSF LV concentrations are higher than predicted by the SBPK model, while the observed brain ECF -to-CSF LV concentration ratio is in accordance with the predicted brain ECF -to-CSF LV concentration ratio. It therefore seems that the plasma-to-brain concentration ratio is increased by disease conditions. Specifically, simulations indicated that the brain ECF -to-CSF concentration ratio in diseased adults and children is equal to 2.6, which is approximately 3-fold lower than the brain ECF -to-CSF concentration ratio observed in healthy rats, being most likely caused by an overestimation of the brain ECF -to-plasma clearance rate. It indicates that under disease conditions there is a decreased active efflux from the brain ECF to plasma (results not shown). On the other hand, simulations indicated that the underestimation of CSF concentrations in disease conditions is most likely caused by an overestimation of the CSF flow. This is in line with the observation that several adult patients had an obstruction to normal CSF flow (Glantz et al., 1998) 
(results not shown).
Overall, the observed and SBPK model predicted plasma u , brain ECF , CSF LV , CSF CM and CSF SAS concentration-time profiles in healthy and diseased rats, dogs, children and adults are summarized in figure 7. (Blakeley et al., 2009) . Adult CSF LV data were obtained from 21 patients with meningeal leukemia or meningeal carcinomatosis (Shapiro et al., 1975) or 16 patients with primary tumor (Glantz et al., 1998) . Child CSF LV data were obtained from 4 patients (serial sampling) with medulloblastoma or ependymoblastoma (Chatelut et al., 1991) . Child CSF SAS data were obtained from 29 patients (single sample) with non-Hodgkin's lymphoma (Vassal et al., 1990 
DISCUSSION
By using the parallel microdialysis probes approach, we have previously shown that, even for acetaminophen, a model compound for passive transport into, within and out of the brain, differences exist between CSF and brain ECF kinetics (Chapter 3). Furthermore, we have also shown that for quinidine, a model compound for P-gp mediated transport, differences exist between CSF and brain ECF kinetics, which are very much dependent of P-gp functionality (Chapter 4). With methotrexate being a substrate for a wide variety of transporters that are all located at the BBB and BCSFB, including RFC1 (Hinken et al., 2011) , BCRP (Breedveld et al., 2007) , MRP 2, 3 and 4 (Vlaming et al., 2011) , OAT 1 and 3 (Takeda et al., 2002) (De Lange et al., 1995) ; (C) diseased rats (De Lange et al., 1995) ; (D) healthy dogs (Neuwelt et al., 1985) ; (E) diseased children (multiple references); (F) In this study, the parallel microdialysis probes approach was used to investigate methotrexate distribution to and within the brain, and the specific contribution of the various transporters on the brain distribution of methotrexate. Probenecid was co-administered as inhibitor of Mrps (Bakos et al., 2000) , Oats (Sugiyama et al., 2001) and Oatps (Kis et al., 2013) . Probenecid is known to inhibit Mrps, Oats and Oatps with a half-maximum inhibition constant (IC50) of approximately 50-300 µg/ml (Bakos et al., 2000) , 5-20 µg/ml (Sugiyama et al., 2001 ) and 1.1 µg/ml (Kis et al., 2013) , respectively. Previous work by Emanuelsson and Paalzow (1988) has indicated that a 150 mg/kg dose of probenecid results in plasma concentrations over 10-fold higher than the IC 50 value up to 3 h after administration. Therefore, it is plausible to assume that the dose of probenecid is sufficient to fully inhibit Mrps, Oats and Oatps throughout the entire experimental period.
We investigated the direct relationships between brain ST methotrexate concentrations and those in different CSF locations, and unbound plasma methotrexate concentrations in the rat. Previous work from our group has indicated that the methotrexate brain ECF -to-plasma total AUC ratio is approximately 5% in healthy rats (De Lange et al., 1995) . Similar findings have been reported for the CSF-to-plasma total AUC ratio (Wang et al., 2003) . When taking into consideration the level of plasma protein binding and the differences in sampling methods, our current results are in line with these findings. Combined results of De Lange et al. (1995), and Wang et al. (2003) , would indicate that brain ECF exposure and CSF exposure are more-or-less similar. However, in the current study, measuring parallelly at both sites within individual rats, we have found that brain ECF exposure of methotrexate is significantly higher than CSF exposure. Inhibition of Mrps, Oats and Oatps by probenecid resulted in a significant increase in brain ECF concentrations only. CSF concentrations seemed to be affected, but not to a significant extent, due to variability (as expected for a drug like methotrexate (Spector and Johanson, 2010) ). Interestingly, the brain ECF -to-CSF concentration ratio was not significantly influenced by co-administration of probenecid. This is in contrast with the P-gp substrate quinidine, for which the relation between brain ECF and CSF concentrations was dependent on P-gp functionality (Chapter 4) Advanced mathematical modeling was applied, using the same structural SBPK model that was previously used for acetaminophen (Chapter 3) and quinidine (Chapter 4). For methotrexate the model parameters were estimated using the experimental data obtained in this study. The resulting SBPK model was further used to predict data obtained in other conditions and species, taking into account changes in physiological parameters.
First, the SBPK model was used to investigate the impact of disease-status on the PK of methotrexate in plasma u and brain ECF of brain tumor-bearing rats, compared to healthy control rats as presented by De Lange et al. (1995) . Figure  4A shows that the model prediction of plasma and brain ECF concentrations is reasonably good. Then, figure 4B shows the SBPK prediction for healthy rat conditions, for rats in which a tumor (rhabdomyosarcoma) had been implanted in the brain (De Lange et al., 1995) . It shows that tumor-bearing rats have specifically increased early methotrexate brain ECF concentrations.
Then, systems-based scaling of our healthy rat data to healthy dogs initially resulted in a 10-to-100-fold underestimation of plasma u and CSF concentrations. However, by taking into account that hepatic elimination of methotrexate in dogs is only a fraction of the renal clearance (Henderson et al., 1965) , the prediction of plasma u and CSF concentrations is much improved. The CSF CM -to-plasma u concentration ratio was predicted correctly. This implicates that the SBPK model of brain distribution developed for the healthy rat seemed to apply correctly for healthy dogs, provided that the hepatic clearance is corrected. Our ultimate aim is to predict human brain distribution, in health and disease. The human methotrexate data available in literature, however, were all obtained under disease conditions, hampering a direct evaluation of the SBPK model in predicting human brain distribution of methotrexate. But, with the assumption that the SBPK model could appropriately predict methotrexate brain distribution in humans, the SBPK model can be used to identify changes brought about by disease conditions. To that end, it should be realized that not only brain diseases can influence brain distribution, as was demonstrated by changes in BBB transport of the permeability marker fluorescein for rats with peripheral inflammation upon chronic exposure to rotenone (Ravenstijn et al., 2008) .
Extrapolation of our healthy rat data to humans with different disease states initially resulted in a 100-fold underestimation of plasma u , brain ECF and CSF concentrations. However, by taking into account that methotrexate undergoes extensive enterohepatic circulation in humans (Hendel and Brodthagen, 1984) , the prediction of plasma u concentrations is much improved. Yet, under the given disease conditions, the brain ECF and CSF concentrations are up to 10-fold higher than predicted for healthy conditions. Using the SBPK model, simulations indicate a possible decreased active efflux from the brain ECF as well as a lower CSF flow under disease conditions. Actually, Glantz et al. (1998) reported that several patients had abnormal (low) CSF flow. It should be realized however, that the human data available from literature reflect methotrexate disposition in body and brain in a variety of diseases that probably do not affect body processes in the same manner. So, more specific data are needed to identify specific disease-related processes that influence brain distribution of methotrexate, and could lead to more personalized treatment.
Alternatively, or in addition, differences between SBPK predicted human healthy and the observed human disease methotrexate data might originate from influences of co-medication, sampling methods and analysis methods (table 4) . Possible species differences in the abundance levels and activities of the different active transport proteins at the BBB and BCSFB, under healthy and diseased conditions, probably also play an important role. It has been previously shown that the genetic variability in transporters in humans leads to an altered sensitivity to methotrexate and thus influences the toxicity and/or efficacy of methotrexate treatment (Kotnik et al., 2011) . This indicates that additional information on the species differences in abundance levels and activities of the different active transport proteins and drug-metabolizing enzymes at the BBB and BCSFB, as well as at the liver and kidney, under healthy or diseased conditions, is essential for extrapolation purposes. 
CONCLUSION
It is concluded that in parallel obtained data on unbound brain ECF , CSF and plasma concentrations, under dynamic conditions, combined with advanced mathematical modeling is a most valid approach to develop SBPK models that allow revealing the mechanisms underlying the relationship between brain ECF and CSF concentrations. In contrast to the P-gp substrate quinidine and P-gp mediated active transport, for methotrexate we have found that inhibition of Mrp/Oat/Oatp-mediated active transport processes does not significantly influence the relationship between brain ECF and CSF concentrations.
Our results suggest that the extrapolation of our healthy rat data to healthy dogs works reasonably well, provided that information on the different elimination routes, or the lack thereof, is included in the systems-based scaling approach. For the correct prediction of plasma u , brain ECF or CSF concentrations in diseased humans, additional information is needed on specific disease states in order to identify which processes are influenced by the disease condition to improve personalized treatment, in which the SBPK model is anticipated to be a useful tool. 
